AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05482893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and PT886 in Part D: Cohort 4
Study NCT05482893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and PT886 in Part D: Cohort 4
Study NCT04372615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inebilizumab
Description: RCP: Blinded treatment on Day 1, Day 15,~* Inebilizumab group: Inebilizumab 300 mg intravenous (IV)~* Placebo group: IV matching placebo Prior to enrollment, all participants will receive standard of care, including high-dose corticosteroids (minimum of 3 days of treatment, 1 g methylprednisolone daily or equivalent) AND either IVIg (total dose range between 1.2 and 2 g/kg) OR plasmapheresis (defined as 5 or 6 exchanges).~Rescue therapy will be given to participants in either treatment group based on the results of the Week 6 assessments. Rescue therapy is cyclophosphamide 750 mg/m2 IV followed by additional doses every 28-30 days until the mRS score is ≤ 3 (at site Principal Investigator's discretion under standard of care).
Study NCT04372615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive IV matching placebo on Day 1 and Day 15,
Study NCT05482893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Chemotherapy as a combination partner to PT886 in Part C: Cohort 2b
Study NCT05255783 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: subcutaneous continuous glucose sensor
Description: Dexcom G6 continuous glucose monitoring system
Study NCT05733429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor imagery therapy
Description: the patients will receive motor imagery therapy for four weeks; the first week will receive kinesthetic imagery, the second week will receive visual imagery, the third week will receive action observation exercises with motor imagery and the fourth week will receive motor control exercises in front of a mirror.
Study NCT05733429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: the patients will receive conventional physical therapy programs in the form of hot packs, therapeutic massage, cervical isometric strengthening exercises, and scapular stabilization exercises.
Study NCT06472050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romosozumab
Description: osteoporosis treatment
Study NCT06472050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: osteoporosis treatment
Study NCT05789420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1R stick
Description: Regular flavor tobacco stick
Study NCT05789420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1M stick
Description: Mentholated flavor tobacco stick
Study NCT05789420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CIG
Description: Subjects' preferred brand of commercially available, regular or mentholated cigarettes
Study NCT05587686 — intervention group
Intervention type: OTHER
Intervention: VentilO application
Description: This educational application provides clinicians with combinations of tidal volume and respiratory rate based on gender, height, weight, body temperature and patient type. The algorithm used is based on published data regarding ventilatory requirements in different populations (i.e. from intubated patients for scheduled surgery to the most severe ICU patients) and anatomical and instrumental dead space.~The objective of this application is to help implement personalized protective ventilation in intubated patients according to their characteristics.~After patient data entry in the VentilO appllication we will compare the recommended settings (for mechanical ventilation) vs the real clinicial settings done by clinician after patient intubation.We will evaluated the potential effect of the VentilO recommendation on the first arterial (or capillary) blood gases compared to the real settings.
Study NCT05733429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: the patients will receive conventional physical therapy programs in the form of hot packs, therapeutic massage, cervical isometric strengthening exercises, and scapular stabilization exercises.
Study NCT06216275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Snoezelen-Aromatherapy-Personal Item Therapy
Description: Intervention Description:~This unique intervention combines three distinct therapeutic approaches specifically tailored for Arab elderly patients with dementia experiencing agitation.~Snoezelen Therapy: Customized sessions in a Snoezelen environment - a specialized room designed to deliver controlled multi-sensory stimuli. This room features adaptable lighting, colors, sounds, and textures to provide a soothing and stimulating experience. Sessions are personalized based on each patient's response and preference, under the guidance of trained professionals.~Aromatherapy: Carefully selected essential oils known for their calming properties are used in a culturally sensitive manner. These oils are diffused in the environment or used during individual sessions to provide a relaxing olfactory experience. The choice of oils and method of delivery are standardized
Study NCT05317000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination 5-azacytidine and nivolumab
Description: The primary objective of the study is to determine whether exposure to the demethylating agent 5-azacytidine will sensitize HPV-associated oropharynx cancer to nivolumab by induction of interferon response, neoantigen expression, and augmentation of lymphocyte infiltration of the tumor microenvironment.
Study NCT05317000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-azacytidine
Description: Chemotherapy is the use of drugs to destroy cancer cells. It usually works by keeping the cancer cells from growing, dividing, and making more cells. Because cancer cells usually grow and divide faster than normal cells, chemotherapy has more of an effect on cancer cells. 5-azacytidine works by slowing down the growth of cancer cells. 5-azacytidine has been demonstrated to improve the cell's ability to make some proteins which signal to the immune system.
Study NCT05317000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Immunotherapy is a type of treatment that uses your body's own immune system to help fight cancer. Specifically, Nivolumab belongs to a class of anti-cancer drugs known as immune checkpoint inhibitors. Cancer cells are able to turn off the immune system by increasing the production of a protein called PD-1. Nivolumab can block PD-1 and may be able to re-activate the immune response to kill head and neck cancer cells.
Study NCT05565872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Urban training
Description: A community-based exercise intervention (Urban Training) by using public spaces and urban walkable trails, adapted to each patient needs and capabilities
Study NCT05565872 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Urban training
Description: A community-based exercise intervention (Urban Training) by using public spaces and urban walkable trails, adapted to each patient needs and capabilities
Study NCT01691261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05206388
Description: PF-05206388 will be provided as a Retinal Pigment Epithelium living tissue equivalent for intraocular use in the form of a monolayer of Retinal Pigmented Epithelial (RPE) cells immobilized on a polyester membrane. The membrane is approximately 6 mm x 3 mm and will contain a confluent layer of RPE cells, at a nominal dose of 17 mm2. The implant is intended to be life-long.
Study NCT05902767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nuts
Description: * A mix of nuts containing 1 Brazil nut (\~3g), walnuts (15g), hazelnuts (7g), and almonds (7g) to be consumed daily for 90 days.~* Dietary counselling on how to follow the Australian Dietary Guidelines
Study NCT05902767 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: - Dietary counselling on how to follow the Australian Dietary Guidelines
Study NCT06354959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: 8-week community based prehab program
Study NCT05428059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile education
Description: The training content prepared by the researchers will be presented to the expert opinion. After the necessary arrangements, it will be installed on the mobile application. The mobile application will be downloaded to the patients' phones for one month. It will be in live consultation.
Study NCT05813145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week
Study NCT05813145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate 160mg
Description: 25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week in addition to 160mg fenofibrate once daily for 3 month.
Study NCT04541381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Availability of clinical decision support based on pharmacogenomic results.
Description: Availability of clinical decision support based on pharmacogenomic results. These results are designed to provide specific dosing information based on the participant's unique genetics/genomics.
Study NCT05515523 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Adipose Derived (AD) Stromal Vascular Fraction (SVF)
Description: autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain and function associated with OA of the knee joint
Study NCT05919238 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Padeliporfin Vascular Targeted Photodynamic (VTP) therapy
Description: The laser light fiber with inflatable balloon to dam SMA blood flow during light illumination will be placed by an Interventional Radiologist in the SMA via a transfemoral artery approach. The balloon will be inflated to impede blood flow for total of 10 minutes during light illumination
Study NCT05975541 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: No intervention will be carried out in this study. Patients from both groups will be monitored for 12 months through observations at time 0, time 6 months, and 12 months. Questionnaires, good clinical practice samples, and anthropometric measurements will be made to monitor changes in the two groups.
Study NCT04992949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Induction : patients will receive induction treatment with CPX-351 100 U/m2 on days 1, 3, and 5. Patients who fail to achieve CR/CRi after the induction cycle will be offered a second induction course of CPX-351 100 U/m2 on days 1 and 3, at the investigators' discretion. If CR/CRi is not achieved following the second induction cycle, patients will go off study~Consolidation : patients in CR/CRi after induction cycle will receive up to 2 course of consolidation therapy with CPX-351 65 U/m2 on days 1 and 3. CPX351 doses could be reduced to 65 U/m2 on day 1 in case of unacceptable toxicity following the previous course.~Allo-SCT : patients for whom an allo-SCT is planned will receive a maximum of one consolidation cycle
Study NCT04978857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autobiographic movie
Description: viewing an autobiographic film through a virtual reality headset
Study NCT05615467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050
Description: Administered orally.
Study NCT05615467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally.
Study NCT05615467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Administered IV.
Study NCT06105489 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral Sinus Lift using tunnel flap technique
Description: The surgical procedure will involve the following steps:~* A single vertical anterior incision will be made, at least 10 mm mesially to the expected outline of the bony window.~* A full-thickness flap will be carefully elevated to expose the lateral wall of the maxillary sinus.~* A trap door will be created in the lateral wall of the maxillary sinus using either a dedicated piezosurgical insert or a straight handpiece with a 3mm round diamond bur.~* The door will be removed.~* The sinus membrane will be gently elevated using various-shaped curettes until it becomes completely detached from the lateral, inferior, and medial walls of the sinus.~* The maxillary sinus will be filled with a heterologous bone graft with a well-documented efficacy.~* The flaps will be meticulously sutured.
Study NCT06105489 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral Sinus Lift using crestal incision flap
Description: The surgical procedure will involve the following steps:~* A horizontal incision is made on the top of the alveolar ridge, along with two additional releasing incisions in the mesial and distal regions.~* A full-thickness flap will be carefully elevated to expose the lateral wall of the maxillary sinus.~* A trap door will be created in the lateral wall of the maxillary sinus using either a dedicated piezosurgical insert or a straight handpiece with a 3mm round diamond bur.~* The door will be removed.~* The sinus membrane will be gently elevated using various-shaped curettes until it becomes completely detached from the lateral, inferior, and medial walls of the sinus.~* The maxillary sinus will be filled with a heterologous bone graft with a well-documented efficacy.~* The flaps will be meticulously sutured.
Study NCT06146569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
Description: Current will be applied bilaterally from the tragus and turbinate parts of the ear with the VagustimTM device. The current frequency to be used in modulation mode is 10 Hz, and the pulse width is 300 μs (In modulation mode, the pulse rate and width are automatically changed in a loop pattern. The pulse width is reduced by 50% from its original setting in 0.5 seconds; then, the pulse rate is changed in 0.5 seconds, reduced by 50% from the original setting. Total cycle time is 1 second.). The current intensity will be applied for 5 minutes, keeping the current constant where the participant feels comfortable.
Study NCT06146569 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
Description: For 5 minutes, sham applications will be applied using a current-free headset specifically designed for this purpose. Participants will observe the device's functionality, but it will not supply any current.
Study NCT06456294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MHC Outreach Intervention
Description: Adult PC clinics are randomized to receive the MHC Outreach Intervention early (n=7 clinics) vs. delayed (n=7 clinics). In early intervention clinics, patients prescribed chronic opioid therapy, on a chronic opioid registry, and receiving their medication from the intervention clinic are sent emails and letters inviting them to schedule an MHC appointment. Clinical staff at the early intervention clinic are educated to encourage attendance. During MHC visits, MHC staff assess patients prescribed Chronic Opioid Therapy (COT), educate them about overdose, prescribe naloxone, and order guideline-concordant opioid monitoring.
Study NCT04915859 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hand Cooling at 12-15 degrees celsius
Description: hand cooling at 12-15 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature
Study NCT04915859 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hand Cooling at 16-20 degrees celsius
Description: hand cooling at 16-20 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature
Study NCT04915859 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hand and back cooling at 12-15 or 16-20 degrees celsius
Description: hand and back cooling at 12-15 or 16-20 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature while also wearing the back wrap cooling device set to this temperature
Study NCT04915859 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Passive cooling
Description: participants will sit in a chair and passively cool (no active intervention)
Study NCT04840758 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablation Radiotherapy
Description: Stereotactic ablation radiotherapy was performed sequentially on the primary and secondary lesions. 50Gy/4F or 70Gy/10F were used according to the specific location of the tumor。
Study NCT04840758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab was started 2 weeks after the end of radiotherapy. Sintilimab : 200 mg intravenously, Q3W every cycle , given on the D1 of each cycle, and total of 4 cycles
Study NCT06073327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dark chocolate
Description: 30g of dark or white chocolate was provided by the nutritionist for 30 days
Study NCT06073327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: White chocolate
Description: 30g of white chocolate was provided by the nutritionist for 30 days
Study NCT05137262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Given by IV
Study NCT05137262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given by IV
Study NCT05137262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given by IV
Study NCT05137262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given by IV
Study NCT05137262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given by IV
Study NCT05137262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given by IV
Study NCT06395168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined Newborn and Lactation Visit
Description: See Arm/Group Description
Study NCT06538207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4578
Description: Specified dose on specified days
Study NCT06538207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: Specified dose on specified days
Study NCT06538207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Specified dose on specified days
Study NCT06538207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofolinate
Description: Specified dose on specified days
Study NCT06538207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Specified dose on specified days
Study NCT06538207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Specified dose on specified days
Study NCT06538207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Specified dose on specified days
Study NCT06538207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Specified dose on specified days
Study NCT04444362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intestinal Microbiota Transplant (IMT) Capsules
Description: Intestinal Microbiota Transplant (IMT) Capsules tid immediately after cardiovascular surgery for at least 7 days
Study NCT04897334 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 2 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
Study NCT04897334 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 2 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
Study NCT05750524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reflexology hand massage
Description: Reflexology massage methods applied randomly to both trial groups.